Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis
{{output}}
Fibrosis is a key predictor of the long-term prognosis in metabolic dysfunction-associated steatotic liver disease (MASLD). Numerous clinical trials in drug development for MASLD have used fibrosis improvement as an efficacy endpoint. We aim to compare the eff... ...
